In support of this hypothesis, genetic or systemic IKKβ inhibition not only reduces KRAS-induced lung tumour growth by reducing cell proliferation [22,23], but also reduces KRAS-induced angiogenesis [24], a cancer hallmark that is associated with poor prognosis and contributes to the process of metastasis [25]. This evidence concerns the gene KRAS and cancer.